Found 326 Enz. Inhib. hit(s) with all data for entry = 80 TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 4nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 4nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 5.80nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1A(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 6.5nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 7.70nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 8nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 8.60nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1A(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 9.10nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 10nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 11nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 12nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 14nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 15nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1B(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 15nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 16nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 16nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 16nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 17nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 17nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 19nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 19nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 22nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1B(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 22nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 22nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 22nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 23nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 23nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 23nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 24nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 24nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 25nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1B(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 25nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 26nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 27nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 28nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1A(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 29nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 29nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 30nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 30nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 31nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 32nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 32nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 34nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1B(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 38nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 38nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 40nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 41nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 41nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 43nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetActivin receptor type-1(Homo sapiens (Human))
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
Affinity DataIC50: 43nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
